Mutation Burden May Help Guide First-Line Immunotherapy in NSCLC – OncLive
OncLive |
Mutation Burden May Help Guide First-Line Immunotherapy in NSCLC
OncLive Tumor mutational burden (TMB) in non–small cell lung cancer (NSCLC) identified patients who were more likely to respond to first-line combination immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy), an updated analysis of CheckMate-586 … Immunotherapy superior to chemotherapy for advanced lung cancer with high tumor mutational burden Nivolumab/Ipilimumab Significantly Improves PFS in TMB-High NSCLC |
